Structural map of Kaposi sarcoma-associated herpesvirus RNA provides clues to molecular interactions

Apr 20, 2017

Scientists from CCR have generated a comprehensive structural map of Kaposi sarcoma-associated herpesvirus polyadenylated nuclear (PAN) RNA, a long non-coding RNA that helps the virus evade detection by its host’s immune system. The findings open new oppportunites to study the life cycle of this cancer-causing virus.  Learn more...

Center for Cancer Research plays key role in first FDA-approved drug for treatment of Merkel cell carcinoma

Apr 18, 2017

The Center for Cancer Research’s ability to rapidly deploy integrated basic and clinical research teams at a single site facilitated the rapid FDA approval of the immunotherapy drug avelumab for metastatic Merkel cell carcinoma, a rare, aggressive form of skin cancer. Learn more...


New targets for immunotherapy-based treatment of HPV-related cancers

Apr 14, 2017

Scientists at the Center for Cancer Research and three other cancer research institutions show that immunotherapy treatments that resulted in complete regression of metastatic cervical cancer largely targeted two non-viral antigens. Read more…


blood vessels

Antibody-linked drug destroys tumor cells and tumor blood vessels in many types of cancer

Apr 10, 2017

A team led by Brad St. Croix, Ph.D., Senior Associate Scientist, Mouse Cancer Genetics Program, has developed an antibody-drug conjugate (ADC) that destroys both tumor cells and the blood vessels that nourish them. The drug significantly shrank breast tumors, colon tumors and several other types of cancer and prolonged survival. Learn more...


Experimental immunotherapy shows promise in treating metastatic uveal melanoma

Apr 7, 2017

A team led by Udai S. Kammula, M.D., Investigator in the Surgery Branch, has shown that an immunotherapy known as adoptive cell transfer (ACT) is a promising approach to treating a rare form of melanoma that affects the eye.  Learn more...

CCR scientists tease out mechanisms of immune cell communication

Apr 5, 2017

Researchers from the Cancer and Inflammation Program at the Center for Cancer Research and the Ben-Gurion University of the Negev in Israel have discovered that the simple processes of molecular diffusion and absorption control the spread of cytokines through dense body tissues. The simple control mechanisms enable the immune response to tailor itself to the nature and severity of a pathogenic attack and to prevent dangerous autoimmune reactions.  Read more...

Investigators lead first human trials of new immunotherapy drug

Apr 3, 2017

In two early-phase trials, CCR investigators and colleagues show that the immunotherapy drug avelumab can prevent the growth and formation of a variety of advanced solid tumors, including those in previously treated non-small cell lung cancer.  Learn more...

Study shows aspirin reduces the risk and recurrence of prostate cancer in African-American men

Mar 17, 2017

African-American men who take a daily dose of aspirin experience a significantly lower risk of developing advanced prostate cancer – the aggressive and deadly form of the disease – than African-American men who do not regularly use aspirin, according to a study from the Center for Cancer Research (CCR) Laboratory of Human Carcinogenesis. Learn more...

Researchers uncover cause of genetic anomaly linked to cancer

Mar 1, 2017

In a new study in Nature, Shiv Grewal’s team has identified a process that drives a genetic anomaly linked to cancer and other diseases. This work could open new avenues for treatment of cancer and other human diseases. Learn more...

Clinical trial shows new drug combo effective in prostate cancer treatment

Mar 1, 2017

Preliminary results from an ongoing clinical trial from former Clinical Fellow Fatima Karzai shows that PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib work together to reduce the prostate-specific antigen (PSA) number. PSA is a protein produced by cells of the prostate gland and is usually elevated in men with prostate cancer. Eight out of 10 patients in this trial experienced reduction in PSA levels with five patients experiencing a 50 percent or more decrease from baseline. Karzai presented this information at the 2017 Genitourinary Cancers Symposium.

Clinical trial shows new drug combo effective in prostate cancer treatment